Nimotuzumab-induced hypertension: A maiden case report

Ommurugan Balaji, D. Amita Priya, Navin Patil

Research output: Contribution to journalArticle

Abstract

Nimotuzumab is one among the latest humanized monoclonal antibody targeting against epidermal growth factor receptor (EGFR). It is approved for head and neck squamous cancer in India, Srilanka, Cuba and Argentina, for glioma in Cuba, Argentina and Ukraine and nasopharyngeal cancer in China. Hypertension is most common with bevacizumab and cetuximab, which are monoclonal antibodies against EGFR. Hence, we report here a case of nimotuzumab-induced hypertension in a 70-year-old man treated for vocal cord carcinoma.

Original languageEnglish
Pages (from-to)8-9
Number of pages2
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume10
Issue number4
DOIs
Publication statusPublished - 01-04-2017

Fingerprint

Cuba
Argentina
Epidermal Growth Factor Receptor
Nasopharyngeal Neoplasms
Hypertension
Antibodies, Monoclonal, Humanized
Ukraine
Vocal Cords
Head and Neck Neoplasms
Glioma
India
China
Monoclonal Antibodies
Carcinoma
nimotuzumab
Cetuximab
Bevacizumab

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

@article{69686afc4ef34c298c5cd592a43fb2b4,
title = "Nimotuzumab-induced hypertension: A maiden case report",
abstract = "Nimotuzumab is one among the latest humanized monoclonal antibody targeting against epidermal growth factor receptor (EGFR). It is approved for head and neck squamous cancer in India, Srilanka, Cuba and Argentina, for glioma in Cuba, Argentina and Ukraine and nasopharyngeal cancer in China. Hypertension is most common with bevacizumab and cetuximab, which are monoclonal antibodies against EGFR. Hence, we report here a case of nimotuzumab-induced hypertension in a 70-year-old man treated for vocal cord carcinoma.",
author = "Ommurugan Balaji and {Amita Priya}, D. and Navin Patil",
year = "2017",
month = "4",
day = "1",
doi = "10.22159/ajpcr.2017.v10i4.16868",
language = "English",
volume = "10",
pages = "8--9",
journal = "Asian Journal of Pharmaceutical and Clinical Research",
issn = "0974-2441",
publisher = "Innovare Academics Sciences Pvt. Ltd",
number = "4",

}

Nimotuzumab-induced hypertension : A maiden case report. / Balaji, Ommurugan; Amita Priya, D.; Patil, Navin.

In: Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, No. 4, 01.04.2017, p. 8-9.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nimotuzumab-induced hypertension

T2 - A maiden case report

AU - Balaji, Ommurugan

AU - Amita Priya, D.

AU - Patil, Navin

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Nimotuzumab is one among the latest humanized monoclonal antibody targeting against epidermal growth factor receptor (EGFR). It is approved for head and neck squamous cancer in India, Srilanka, Cuba and Argentina, for glioma in Cuba, Argentina and Ukraine and nasopharyngeal cancer in China. Hypertension is most common with bevacizumab and cetuximab, which are monoclonal antibodies against EGFR. Hence, we report here a case of nimotuzumab-induced hypertension in a 70-year-old man treated for vocal cord carcinoma.

AB - Nimotuzumab is one among the latest humanized monoclonal antibody targeting against epidermal growth factor receptor (EGFR). It is approved for head and neck squamous cancer in India, Srilanka, Cuba and Argentina, for glioma in Cuba, Argentina and Ukraine and nasopharyngeal cancer in China. Hypertension is most common with bevacizumab and cetuximab, which are monoclonal antibodies against EGFR. Hence, we report here a case of nimotuzumab-induced hypertension in a 70-year-old man treated for vocal cord carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85017096097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017096097&partnerID=8YFLogxK

U2 - 10.22159/ajpcr.2017.v10i4.16868

DO - 10.22159/ajpcr.2017.v10i4.16868

M3 - Article

AN - SCOPUS:85017096097

VL - 10

SP - 8

EP - 9

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

IS - 4

ER -